trending Market Intelligence /marketintelligence/en/news-insights/trending/wobi_ngn0nioYGtuMDqI-A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Gene-therapy focused Genprex prices IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Gene-therapy focused Genprex prices IPO

Genprex Inc. priced its IPO of between 2.5 million and 4.5 million shares on the Nasdaq Capital Market at $5 apiece.

The clinical stage gene therapy company — which would trade under the "GNPX" symbol will primarily use funds raised to continue developing its lung cancer drug Oncoprex which is currently in phase 2 trial.

The company expects the offering to close on Nov. 6 with Network 1 Financial Securities Inc. acting as its underwriter.